BTIG Believes CTI BioPharma (CTIC) Won’t Stop Here

BTIG analyst Robert Hazlett maintained a Buy rating on CTI BioPharma (CTICResearch Report) yesterday and set a price target of $10.00. The company’s shares closed last Thursday at $4.67, close to its 52-week high of $5.25.

According to, Hazlett is a 3-star analyst with an average return of 5.9% and a 40.6% success rate. Hazlett covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Eiger Biopharmaceuticals, and Nektar Therapeutics.

Currently, the analyst consensus on CTI BioPharma is a Strong Buy with an average price target of $8.12, a 61.1% upside from current levels. In a report released yesterday, Brookline Capital Markets also maintained a Buy rating on the stock with a $12.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $5.25 and a one-year low of $1.43. Currently, CTI BioPharma has an average volume of 4.82M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CTI BioPharma Corp. operates as a biopharmaceutical company, which focuses on the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. Its products include PIXUVRI, Pacritinib, Tosedostat and Opaxio. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

Read More on CTIC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More